Gastric Bypass Surgery — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Roux-en-Y gastric bypass (RYGB) is the gold-standard bariatric surgical procedure for severe obesity, combining gastric restriction with intestinal rerouting and profound alterations in gut hormones regulating appetite, satiety, and glucose metabolism. A small gastric pouch of approximately 30–50 mL (compared with the normal stomach capacity of 1,000–1,500 mL) is created by stapling across the stomach, drastically limiting food intake volume. This pouch is connected directly to the mid-jejunum — bypassing the remaining stomach, entire duodenum, and proximal 50–100 cm of jejunum — eliminating absorption through these segments and reducing caloric and nutrient absorption. The bypassed stomach segment remains in situ, connected lower down the small bowel in the Y-shaped configuration that gives the procedure its name. The metabolic effects of RYGB extend far beyond restriction and malabsorption: dramatic increases in post-meal GLP-1 (glucagon-like peptide-1) and PYY secretion suppress appetite and stimulate pancreatic insulin release, producing rapid improvement in type 2 diabetes that often precedes significant weight loss. RYGB is the most studied bariatric procedure with over 30 years of robust long-term outcome data and remains the preferred procedure for patients with severe gastro-oesophageal reflux disease, type 2 diabetes, or metabolic syndrome.

NICE, IFSO, and ASMBS criteria for bariatric surgery including RYGB are: BMI ≥40 kg/m² with or without obesity-related comorbidities, or BMI ≥35 kg/m² with at least one significant obesity-related comorbidity (type 2 diabetes, hypertension, obstructive sleep apnoea, fatty liver disease with fibrosis, osteoarthritis, depression related to obesity). In patients with type 2 diabetes poorly controlled despite optimal medical therapy, surgery may be considered at BMI ≥30 kg/m² given the evidence of superior glycaemic outcomes. Patients must have attempted and failed to achieve or maintain adequate weight loss with supervised conservative management (diet, exercise, behavioural therapy) for at least 6–12 months. RYGB is specifically preferred over sleeve gastrectomy (the alternative major bariatric procedure) in patients with severe GORD or Barrett's oesophagus (sleeve gastrectomy worsens reflux), type 2 diabetes (RYGB achieves superior remission rates), and failed sleeve gastrectomy. Comprehensive pre-operative assessment is mandatory, including psychological evaluation, dietitian consultation, cardiopulmonary fitness assessment, upper GI endoscopy, and sleep study if sleep apnoea is suspected. Relative contraindications include current tobacco smoking (must stop 6 weeks pre-surgery), active depression or psychosis not adequately treated, and inability to commit to lifelong dietary and supplement changes.

RYGB is performed laparoscopically under general anaesthesia using 5–6 trocars, with the patient in a reverse Trendelenburg position. Creation of the gastric pouch: a linear stapler divides the stomach horizontally just below the gastro-oesophageal junction, creating a small proximal pouch of 30–50 mL. Reinforcing sutures may be applied to the staple line to reduce leak risk. Roux limb construction: the proximal small bowel is divided approximately 50–100 cm distal to the Treitz ligament. The distal (Roux) limb — 75–150 cm in length — is brought up to the gastric pouch in an antecolic, antegastric configuration. Gastrojejunostomy: the Roux limb end is anastomosed to the gastric pouch using a 25 mm circular stapler or linear stapler, creating a gastric outlet of 12–15 mm. The proximal bypassed biliopancreatic limb is anastomosed to the Roux limb 75–150 cm distal to the gastrojejunostomy (jejunojejunostomy) in the Y-configuration, completing the anatomical reconstruction. All mesenteric defects (Peterson's and jejunojejunostomy mesentery) are sutured closed to prevent internal hernias. The anastomoses are tested with methylene blue or air under saline to check for leaks. Total operating time is 2–3 hours; a robotic platform is increasingly used at specialist bariatric centres for precision in anastomotic construction. Total operative time for laparoscopic RYGB is typically 90–180 minutes.

RYGB achieves excess weight loss (EWL) of 60–80% at 1–2 years — the primary bariatric outcome measure. Total body weight loss of 30–40% is typical at 12–18 months. Type 2 diabetes remission (normal fasting glucose and HbA1c without medication) occurs in 75–85% of patients — often within days to weeks of surgery before significant weight loss, demonstrating that the metabolic improvement is mediated by gut hormone changes (GLP-1 surge), not purely caloric restriction. Resolution of obesity comorbidities: hypertension remits in 60–75%, dyslipidaemia in 70%, obstructive sleep apnoea in 80–90%, and non-alcoholic steatohepatitis (NASH) in 85–90% of operated patients. The Swedish Obese Subjects (SOS) study — a 20-year prospective controlled trial — demonstrated a 29% reduction in all-cause mortality in bariatric surgery patients versus controls, with 78% reduction in diabetes incidence, 34% reduction in cardiovascular events, and 33% reduction in cancer-related mortality. At 10 years, maintained excess weight loss averages 50–60% with appropriate lifestyle adherence; some weight regain (5–20% of lost weight) is expected and is not treatment failure. Quality of life improvements across multiple domains (physical function, depression, sexual function, mobility) are consistently demonstrated in long-term follow-up studies.

Serious early complications occur in 3–5% of patients at accredited bariatric centres. Anastomotic leak — most feared complication — occurs in 1–2% of RYGB and usually presents with tachycardia and abdominal pain on day 2–5; it requires urgent CT, drain, endoscopic stent or nasogastric tube placement, and occasionally surgical re-intervention. Pulmonary embolism (PE) and deep venous thrombosis (DVT) affect 0.5–1% despite aggressive prophylaxis (LMWH, sequential compression devices, early mobilisation); PE is the leading cause of 30-day mortality. Internal hernia through the mesenteric defects — a late complication occurring months to years post-surgery — affects 1–3% of patients and presents with intermittent or acute-onset abdominal pain and nausea, requiring urgent CT and laparoscopic repair. Dumping syndrome — early (nausea, diaphoresis, tachycardia 15–30 min after eating from rapid gastric emptying) and late (reactive hypoglycaemia 1–3 hours post-meal from GLP-1 surge) — affects 10–20% of patients to varying degrees and is managed with dietary modification. Nutritional deficiencies — iron, vitamin B12, folate, vitamin D, calcium — are universal long-term risks; lifelong supplementation and annual blood monitoring are mandatory. Marginal ulcers (peptic ulcers at the gastrojejunal anastomosis) occur in 1–3% and are related to NSAID use, smoking, and H. pylori infection. 30-day mortality at accredited centres is below 0.2%.

Patients begin clear liquids on day 1 post-surgery and progress through a structured dietary pathway: full liquids for 2 weeks, pureed foods at 2–4 weeks, soft foods at 4–6 weeks, and a regular bariatric diet from 6–8 weeks onwards. Portion sizes are permanently small — 100–150 mL initially increasing to 200–250 mL over months. The protein-first eating principle — consuming protein (30–40 g per meal target) before carbohydrates and fats at every meal — is essential to prevent muscle loss. Hospital discharge is typically at 2–3 days after laparoscopic RYGB. Return to desk work at 2–3 weeks; manual labour at 6–8 weeks. Driving from 1–2 weeks. Lifelong nutritional supplementation is mandatory: a bariatric-specific multivitamin, vitamin B12 (sublingual tablets or 3-monthly injections — intrinsic factor is bypassed so oral absorption is impaired), iron (with vitamin C for absorption), calcium citrate (not carbonate, which requires gastric acid for absorption), vitamin D, and folate. Annual blood monitoring including full blood count, iron studies, B12, folate, vitamin D, PTH, zinc, and copper is required. Psychological support for body image and emotional eating behaviours, physiotherapy for progressive exercise capacity, and ongoing dietitian guidance are integral components of post-operative bariatric care. Bariatric follow-up continues for a minimum of 5 years with 6-monthly then annual clinic visits.